Season 2025 Episode 680
What if a drug could help chemotherapy patients continue treatment without painful side effects? Hoth Therapeutics (NASDAQ: HOTH) is making that possible by developing innovative treatments that address unmet medical needs and help patients maintain their therapy safely.
In this interview, CEO Robb Knie discusses HT001, the company’s lead drug currently in Phase 2 trials for chemotherapy-induced rash, and HTKIT, which shows promise in cancer treatment. He also shares how the company is advancing programs for Alzheimer’s and obesity, including an obesity drug licensed from the U.S. Department of Veterans Affairs.
With a diversified pipeline, a patient-focused approach, and strategic use of AI to de-risk and accelerate development, Hoth Therapeutics is positioning itself as a biotech company to watch.
Learn more about Hoth Therapeutics: https://hoththerapeutics.com
Watch the full YouTube interview here: https://youtu.be/AYQa3g6dVLA?si=w_zDH0TaSxP3m6Ji
And follow us to stay updated: https://www.youtube.com/@GlobalOneMedia?sub_confirmation=1
Published on 3 months, 1 week ago
If you like Podbriefly.com, please consider donating to support the ongoing development.
Donate